CANADIAN PATENTED DRUG PRICES DECLINED .3% FOR FIRST HALF OF 1993
CANADIAN PATENTED DRUG PRICES DECLINED .3% FOR FIRST HALF OF 1993 from the same period in 1992, the Canadian Patented Medicine Prices Review Board reports in its January 1994 Bulletin. This is the first time that the Patented Medicine Price Index, which measures patented drug prices at the manufacturer level, has declined. The decline comes at a time when the Canadian Consumer Price Index rose 1.9% and the pharmaceutical component of the Industrial Product Price Index was up 1.3%.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth